Advanced
lipid-based
platform

Prof. Yechezkel Barenholz is a world-renowned professor of biochemistry at the Hebrew University of Jerusalem and the head of the Liposome and Membrane Research Lab. He has co-authored over 440 publications with more than 47,700 citations and holds over 55 patents, more than half of which have been licensed. Prof. Barenholz is one of the key inventors of Doxil®, the first FDA-approved nano-drug for cancer treatment. He has co-founded six startups and is currently developing six additional liposomal drugs for various medical applications. His work bridges biology, nanotechnology, and medicine. Among his many awards, he received the 2020 EMET Prize for Nanotechnology, and he is ranked among the top 2,500 scientists globally.

Prof. Itzhak Haviv has co-authored 143 peer-reviewed papers, with 8,661 citations and an H-index of 43. His cancer research career includes postdoctoral work at UC Berkeley and founding one of the first precision medicine services at Peter MacCallum Cancer Centre. He co-founded the NICTA life science program in Australia and Israel's fifth medical school, playing a key role in biomedical research and COVID-19 pandemic control strategies.

Prof. Herve Bercovier has been a Full Professor of Clinical Microbiology at the Hebrew University of Jerusalem since 1989. His research spans infectious diseases, including the development of a vaccine against fish pathogens, and immuno-regulation therapies for diseases like asthma and Alzheimer's. During the COVID-19 pandemic, he collaborated on vaccine responses in the elderly and worked on developing new vaccines with Prof. Barenholz and Dr. Rouvinski.

Dr. Alexander Rouvinski is a researcher in the Department of Microbiology and Molecular Genetics at the Institute for Medical Research Israel-Canada (IMRIC) at the Hebrew University-Hadassah Medical School. His lab studies virus-host interactions, viral structure, and neutralization mechanisms, focusing on arboviruses such as Dengue, Chikungunya, and West Nile. Dr. Rouvinski's research also explores zoonotic viruses, including coronaviruses like SARS-CoV-2, aiming to understand host restriction, immune response, and viral pathogenesis through advanced techniques like electron microscopy and X-ray crystallography.

Dr. Ahuva Cern is a senior researcher and product director at the Lab of Membrane and Liposome Research at the Hebrew University. She previously served as Associate Director at Pharmos Ltd. and Director of Formulation Development at Nextar Chempharma Solutions. Dr. Cern has led numerous formulation development projects and is a key inventor of several patents, including those for liposomal mupirocin.

Dr. Keren Turjeman is the director of the Barenholz Laboratory at the Hebrew University-Hadassah Medical School. Specializing in liposome and lipid nanoparticle-based drug products, her work spans cancer therapy, autoimmune diseases, and inflammation. Dr. Turjeman has co-authored over 30 scientific papers and is a co-inventor on five granted patents. Her expertise includes bio-analytics, toxicology, and quality control in accordance with FDA guidelines.

Dr. Reuven Weiner leads a lab at the Hebrew University School of Medicine, focusing on the molecular mechanisms of protein modifications by ubiquitin and ubiquitin-like proteins in health and disease. Prior to establishing his own lab, Dr. Weiner conducted postdoctoral research at Johns Hopkins School of Medicine (Baltimore, MD), supported by the Howard Hughes Medical Institute.